J&J sees continued supply shortages of cancer drug (Reuters)
Reuters – Johnson & Johnson has told doctors it expects a limited supply of its Doxil cancer drug to become available within the next six weeks, but warned the amount would not be sufficient for all patients currently on waiting lists.
View full post on Yahoo! News: Health News
Leave a Reply